A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

ABSTRACT: Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor-positive (ER⁺) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER⁺ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER⁺ breast cancer.Experimental Design: Potential eligible patients with clinical stage II/III ER⁺/HER2^- breast cancer were preregistered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing. Pat

SUBMITTER: Ma CX 

PROVIDER: S-EPMC6392430 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature